Salt intake and plasma atrial natriuretic peptide and nitric oxide in hypertension

Hypertension

Volumn 28, Issue 3, 1996, Pages 335-340

  Campese, Vito M ^a,e   Tawadrous, Medhat ^f   Bigazzi, Roberto ^b   Bianchi, Stefano ^b   Mann, Amardeep S ^a   Oparil, Suzanne ^c   Raij, Leopoldo ^d  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b Unitá Operativa Nefrologia   (Italy)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d UNIVERSITY OF MINNESOTA   (United States)

^e LAC USC MEDICAL CENTER   (United States)

^f NONE

Author keywords

blacks; hypertension, sodium dependent; natriuretic peptides; nitric oxide; sodium, dietary endothelium derived factor

Indexed keywords

ATRIAL NATRIURETIC FACTOR; NITRIC OXIDE; SODIUM CHLORIDE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERTENSION; MALE; NATRIURESIS; PEPTIDE ANALYSIS; PRIORITY JOURNAL; PROTEIN SECRETION; RACE DIFFERENCE; SALT INTAKE; SODIUM RETENTION; VASCULAR RESISTANCE;

EID: 0029820868     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.28.3.335     Document Type: Article

References (71)

1. Campese VM. Salt-sensitivity in hypertension: renal and cardiovascular implications. Hypertension. 1994;23:531-550.
2. Luft FC, Miller JZ, Grim CE, Fineberg NS, Christian JC, Daugherty SA, Weinberger MH. Salt-sensitivity and resistance of blood pressure: age and race as factors in physiological responses. Hypertension. 1991;17(suppl I):I-102-I-108.
3. Campese VM, Parise M, Karubian F, Bigazzi R. Abnormal renal hemodynamics in black salt-sensitive patients with hypertension. Hypertension. 1991;18:805-812.
4. Campese VM, Romoff M, Levitan D, Saglikes Y, Friedler RM, Massry SG. Abnormal relationship between sodium intake and sympathetic nervous system activity in salt-sensitive patients with essential hypertension. Kidney Int. 1982;21:371-378.
5. Fujita T, Henry WL, Bartter FC, Lake CR, Delea CS. Factors influencing blood pressure in salt-sensitive patients with hypertension. Am J Med. 1980;69:334-344.
6. Skrabal F, Herholz H, Neumayr M, Hamberger L, Ledochowski M, Sporer H, Hortnagl H, Schwarz S, Schonitzer D. Salt sensitivity in humans is linked to enhanced sympathetic responsiveness and to enhanced proximal tubular reabsorption. Hypertension. 1984;6:152-158.
7. Koolen MI, van Brummelen P. Adrenergic activity and peripheral hemodynamics in relation to sodium sensitivity in patients with essential hypertension. Hypertension. 1984;6:820-825.
8. Gill JR, Gullner HG, Lake CR, Lakatua DJ, Lan G. Plasma and urinary catecholamines in salt-sensitive idiopathic hypertension. Hypertension. 1988;11:312-319.
9. Levy SB, Lilley JJ, Frigon RP, Stone RA. Urinary kallikrein and plasma renin activity as determinants of renal blood flow: the influence of race and dietary sodium intake. J Clin Invest. 1977;60:129-138.
10. Zinner SH, Margolius HS, Rosner B, Keiser HR, Kass EH. Familial aggregation of urinary kallikrein concentration in childhood: relation to blood pressure, race and urinary electrolytes. J Epidemiol. 1976; 104:124-132.
11. Holland OB, Chud JM, Braunstein H. Urinary kallikrein excretion in essential and mineralocorticoid hypertension. J Clin Invest. 1980; 65:347-356.
12. De Bold AJ. Atrial natriuretic factor: a hormone produced by the heart. Science. 1985;230:767-770.
13. Mimram A, Nussberger J, Ribstein J, Waeber B, Brunner HR. Response of atrial natriuretic peptide to acute saline loading in essential hypertension. Am J Physiol. 1988;255:F1085-F1090.
14. Brunner HR, Biollaz J, Nussberger J, Waeber B. Effects of atrial natriuretic peptide in man. Curr Opin Cardiol. 1987;2:671-677.
15. Richards AM, Espiner EA, Ikram H, Yandle TG. Atrial natriuretic factor in hypertension: bioactivity at normal plasma levels. Hypertension. 1989;14:261-268.
16. Janssen WMT, De Zeeuw D, van der Hem GK, De Jong PE. Anti-hypertensive effect of a 5-day infusion of atrial natriuretic factor in humans. Hypertension. 1989;13:640-646.
17. Oparil S. The elusive role of atrial natriuretic peptide in hypertension. Mayo Clin Proc. 1995;70:1015-1017. Editorial.
18. John SWM, Krege JH, Oliver PM, Hagaman JR, Hodgin JB, Pang SC, Flynn TG, Smithies O. Genetic decreases in atrial natriuretic peptide and salt-sensitive hypertension. Science. 1995;267:679-681.
19. Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature. 1980;288:373-376.
20. Palmer RM, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature. 1987;327:524-526.
21. Murad F, Mittal CK, Arnold WP, Katsuki S, Kimura H. Guanylate cyclase: activation by azide, nitro compounds, nitric oxide, and hydroxyl radical and inhibition by hemoglobin and myoglobin. Adv Cyclic Nucleotide Res. 1978;9:145-158.
22. Collins P, Griffith TM, Henderson AH, Lewis MJ. Endothelium-derived relaxing factor alters calcium fluxes in rabbit aorta: a cyclic guanosine monophosphate-mediated effect. J Physiol (Lond). 1986; 381:427-437.
23. Bolotina VM, Najibi S, Palacino JJ, Pagano PJ, Cohen RA. Nitric oxide directly activates calcium-dependent potassium channels in vascular smooth muscle. Nature. 1994;368:850-853.
24. Konishi M, Su C. Role of endothelium in dilator responses of spontaneously hypertensive rat arteries. Hypertension. 1983;5:881-886.
25. Lockette W, Otsuka Y, Carretero OA. The loss of endothelium-dependent vascular relaxation in hypertension. Hypertension. 1986;8(suppl II):II-61-II-66.
26. Luscher TF, Raij L, Vanhoutte PM. Endothelium-dependent responses in normotensive and hypertensive Dahl rats. Hypertension. 1987;9:157-163.
27. Luscher TF. The endothelium: target and promoter of hypertension? Hypertension. 1990;15:482-485.
28. Huang PL, Huang Z, Mashimo H, Bloch KD, Moskowitz MA, Bevan JA, Fishman MC. Hypertension in mice lacking the gene for endothelia nitric oxide synthase. Nature. 1995;377:239-242.
29. Luscher TF, Boulanger CM, Yang Z, Noll G, Dohi Y. Interactions between endothelium-derived relaxing and contracting factors in health and cardiovascular disease. Circulation. 1993;87(suppl V):V-36-V-44.
30. G-monomethyl-L-arginine in patients with hypertension: the nitric oxide dilator mechanism appears abnormal. J Hypertens. 1992;10:1025-1031.
31. Cockcroft JR, Chowienczyk PJ, Benjamin N, Ritter JM. Preserved endothelium-dependent vasodilation in patients with essential hypertension. N Engl J Med. 1994;330:1036-1040.
32. Panza JA, Quyyumi AA, Brush JE Jr, Epstein SE. Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension. N Engl J Med. 1990;323:22-27.
33. Linder L, Kiowski W, Buhler FR, Luscher TF. Indirect evidence for release of endothelium-derived relaxing factor in human forearm circulation in vivo: blunted response in essential hypertension. Circulation. 1990;81:1762-1767.
34. Taddei S, Virdis A, Mattei P, Salvetti A. Vasodilation to acetylcholine in primary and secondary forms of human hypertension. Hypertension. 1993;21:929-933.
35. Shultz PJ, Tolins JP. Adaptation to increased dietary salt intake in the rat: role of endogenous nitric oxide. J Clin Invest. 1993;91:1993-1997.
36. Deng X, Welch WJ, Wilcox CS. Renal vasoconstriction during inhibition of NO synthase: effects of dietary salt. Kidney Int. 1994; 46:639-646.
37. Takenaka T, Forster H, De Micheli A, Epstein M. Impaired myogenic responsiveness of renal microvessels in Dahl salt-sensitive rats. Circ Res. 1992;71:471-480.
38. Coyle P. High NaCl predisposes Dahl rats to cerebral infarction after middle cerebral artery occlusion. Hypertension. 1988;12:96-101.
39. Boegehold MA. Flow-dependent arteriolar dilation in normotensive rats fed low- or high-salt diets. Am J Physiol. 1995;269:H407-H414.
40. Chen PY, Sanders PW. L-arginine abrogates salt-sensitive hypertension in Dahl/Rapp rats. J Clin Invest. 1991;88:1559-1567.
41. Panza JA, Casino PR, Badar DM, Quyyumi AA. Effect of increased availability of endothelium-derived nitric oxide precursor on endothelium-dependent vascular relaxation in normal subjects and in patients with essential hypertension. Circulation. 1993;87:1475-1481.
42. Bartholomew B. A rapid method for the assay of nitrate in urine using the nitrate reductase enzyme of Escherichia coli. Food Chem Toxicol. 1984;22:541-543.
43. Granger DL, Hibbs JB Jr, Perfect JR, Durack DT. Metabolic fate of L-arginine in relation to microbiostatic capability of murine macrophages. J Clin Invest. 1990;85:264-273.
44. Tolins JP, Raij L. Effects of amino acid infusion on renal hemodynamics: role of endothelium-derived relaxing factor. Hypertension. 1991;17:1045-1051.
45. 15N nitrate in biological fluids. Anal Biochem. 1982;126:131-138.
46. Shultz PJ, Raij L. Endogenously synthesized nitric oxide prevents endotoxin-induced glomerular thrombosis. J Clin Invest. 1992;90: 1718-1725.
47. Shultz PJ, Tayeh MA, Marletta MA, Raij L. Synthesis and action of nitric oxide in rat glomerular mesangial cells. Am J Physiol. 1991; 261:F600-F606.
48. Tanaka I, Misono KS, Inagami T. Atrial natriuretic factor in rat hypothalamus, atria and plasma: determination by specific radioimmunoassay. Biochem Biophys Res Commun. 1984;124:663-667.
49. Eskay R, Zukowska-Grojec Z, Haass M, Dave JR, Zamir N. Characterization of circulating atrial natriuretic peptides in conscious rats: regulation of release by multiple factors. Science. 1986;232:636-639.
50. Schiffrin EL, St-Louis J, Essiambre R. Platelet binding sites and plasma concentration of atrial natriuretic peptide in patients with essential hypertension. J Hypertens. 1988;6:565-572.
51. Nakaoka H, Kitahara Y, Amano M, Imataka K, Fujii J, Ishibashi M, Yamaji T. Effect of β-adrenoreceptor blockade on atrial natriuretic peptide in essential hypertension. Hypertension. 1987;10:221-225.
52. Talartschik J, Eisenhauer T, Schrader J, Schoel G, Buhr-Schinner H, Scheler F. Low atrial natriuretic peptide plasma concentrations in 100 patients with essential hypertension. Am J Hypertens. 1990;3:45-47.
53. Montorsi P, Tonolo G, Polonia J, Hepburn D, Richards M. Correlates of plasma atrial natriuretic factor in health and hypertension. Hypertension. 1987;10:570-576.
54. Kohno M, Yasunari K, Toshifumi M, Murakawa K, Takeda T. Circulating atrial natriuretic polypeptide in essential hypertension. Am Heart J. 1987;113:1160-1163.
55. Dessi-Fulgheri P, Palermo R, DiNoto G, Conti V, Rinaldi L, Tesei G, Russo P, Rappelli A. Plasma levels of atrial natriuretic factor in mild to moderate hypertensives without signs of left ventricular hypertrophy: correlation with the known duration of hypertension. J Hum Hypertens. 1988;2:177-182.
56. Sagnella GA, Markandu ND, Buckley MG, Miller MA, Singer DRJ, Cappuccio FP, MacGregor GA. Atrial natriuretic peptides in essential hypertension: basal plasma levels and relationship to sodium balance. Can J Physiol Pharmacol. 1991;69:1592-1600.
57. Kohno M, Yasunari K, Murakawa K, Matsuura T, Takeda T. Effects of high-sodium and low-sodium intake on circulating atrial natriuretic peptides in salt-sensitive patients with essential hypertension. Am J Cardiol. 1987;59:1212-1213.
58. Nimura S. Attenuated release of atrial natriuretic factor due to sodium loading in salt-sensitive essential hypertension. Jpn Heart J. 1991; 32:167-178.
59. Ferrari P, Weidmann P, Ferner C, Dietler R, Hollmann R, Piso RJ, Wey J, Shaw S. Dysregulation of atrial natriuretic factor in hypertension-prone man. J Clin Endocrinol Metab. 1990;71:944-951.
60. Weidmann P, Ferrari P, Allemann Y, Ferner C, Shaw SG. Developing essential hypertension: a syndrome involving ANF deficiency? Can J Physiol Pharmacol. 1991;69:1582-1591.
61. Jin H, Chen YF, Yang RH, Meng Qc, Oparil S. Impaired release of atrial natriuretic factor in NaCl loaded spontaneously hypertensive rats. Hypertension. 1988;11:739-744.
62. Jin H, Yang RH, Chen YF, Oparil S. Atrial natriuretic factor prevents NaCl-sensitive hypertension in spontaneously hypertensive rats. Hypertension. 1990;15:170-176.
63. Onwochei MO, Rapp JP. Hyposecretion of atrial natriuretic factor by prehypertensive Dahl salt-sensitive rat. Hypertension. 1989;13:440-448.
64. Romoff MS, Keusch G, Campese VM, Wang MS, Friedler RM, Weidmann P, Massry SG. Effect of sodium intake on plasma catecholamines in normal subjects. J Clin Endocrinol Metab. 1979; 48:26-31.
65. Martin W, Furchgott RF, Villani GM, Jothianandan D. Depression of contractile responses in rat aorta by spontaneously released endothelium-derived relaxing factor. J Pharmacol Exp Ther. 1986; 237:529-538.
66. Vargas HM, Ignarro LJ, Chaudhuri G. Physiological release of nitric oxide is dependent on the level of vascular tone. Eur J Pharmacol. 1990;190:393-397.
67. Adeagbo ASO, Tabrizchi R, Triggle CR. The effects of perfusion rate and NG-nitro-L-arginine methyl ester on cirazoline- and KCl-induced responses in the perfused mesenteric arterial bed of rats. Br J Pharmacol. 1994;111:13-20.
68. Panza JA, Casino PR, Kilcoyne CM, Quyyumi AA. Role of endothelium-derived nitric oxide in the abnormal endothelium-dependent vascular relaxation of patients with essential hypertension. Circulation. 1993;87: 1468-1474.
69. Sessa WC, Pritchard K, Seyedi N, Wang J, Hintze TH. Chronic exercise in dogs increases coronary vascular nitric oxide production and endothelial cell nitric oxide synthase gene expression. Circ Res. 1994;74:349-353.
70. Ambring A, Benthin G, Petersson AS, Jungersten L, Wennmalm A. Indirect evidence of increased expression of NO synthase in marathon runners, and upregulation of NO synthase activity during running. Circulation. 1994;90:732A.
71. Hishikawa K, Nakaki T, Suzuki H, Kato R, Saruta T. Role of L-arginine-nitric oxide pathway in hypertension. J Hypertens. 1993; 11:639-645.